title: Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966.
abstract: The present study examined delta 9-tetrahydrocannabinol (THC)-induced alterations in monoamine transmission in the rat forebrain as well as the effects of the enantiomers of 3-amino-1-hydroxypyrrolid-2-one (HA966) on the monoamine response to THC. Activation of dopamine (DA) and norepinephrine (NE) but not serotonin (5-HT) turnover in the prefrontal cortex (PFC) was observed after THC (5 mg/kg i.p.) administration. Both enantiomers of HA966 completely prevented the effects of THC on PFC DA turnover and partially blocked the THC-induced rise in NE metabolism. The cognitive consequences of THC exposure were also examined. THC significantly impaired spatial working, but not reference, memory in rats, and this effect was ameliorated by HA966. Thus, HA966 prevents the THC-induced increases in PFC DA turnover and impairments of prefrontal cortical working memory function. Furthermore, these data suggest that cognitive impairments displayed by marijuana self-administering humans may be related to PFC DA hyperactivity and that HA966 may prevent this effect.
authors.affiliation: Section of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Jentsch
authors.forename: E
authors.initials: E
authors.lastname: Andrusiak
authors.forename: A
authors.initials: A
authors.lastname: Tran
authors.forename: M B
authors.initials: MB
authors.lastname: Bowers
authors.forename: R H
authors.initials: RH
authors.lastname: Roth
mesh_terms: D000818:Animals; D002395:Catecholamines / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D003071:Cognition / Q000187:drug effects; D013759:Dronabinol / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004563:Electrochemistry; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D006213:Hallucinogens / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008297:Male; D008570:Memory, Short-Term / Q000187:drug effects*; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism*; D011760:Pyrrolidinones / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013028:Space Perception / Q000187:drug effects*
chemical_list: D002395:Catecholamines; D018690:Excitatory Amino Acid Agonists; D006213:Hallucinogens; D011760:Pyrrolidinones; D013759:Dronabinol; C001369:1-hydroxy-3-amino-2-pyrrolidone; D009638:Norepinephrine